JP2014528247A - 神経変性状態の刺激誘発性ゲノムプロファイルマーカー - Google Patents

神経変性状態の刺激誘発性ゲノムプロファイルマーカー Download PDF

Info

Publication number
JP2014528247A
JP2014528247A JP2014534811A JP2014534811A JP2014528247A JP 2014528247 A JP2014528247 A JP 2014528247A JP 2014534811 A JP2014534811 A JP 2014534811A JP 2014534811 A JP2014534811 A JP 2014534811A JP 2014528247 A JP2014528247 A JP 2014528247A
Authority
JP
Japan
Prior art keywords
gene
expression
cell
cell sample
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534811A
Other languages
English (en)
Japanese (ja)
Inventor
アルコン、ダニエル・エル．
カーン、タパン・ケー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2014528247A publication Critical patent/JP2014528247A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2014534811A 2011-10-05 2012-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー Pending JP2014528247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543416P 2011-10-05 2011-10-05
US61/543,416 2011-10-05
PCT/US2012/059137 WO2013052922A1 (en) 2011-10-05 2012-10-05 Stimulus-elicited genomic profile markers of a neurodegenerative condition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017195118A Division JP6636488B2 (ja) 2011-10-05 2017-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Publications (1)

Publication Number Publication Date
JP2014528247A true JP2014528247A (ja) 2014-10-27

Family

ID=47116384

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014534811A Pending JP2014528247A (ja) 2011-10-05 2012-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー
JP2017195118A Active JP6636488B2 (ja) 2011-10-05 2017-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017195118A Active JP6636488B2 (ja) 2011-10-05 2017-10-05 神経変性状態の刺激誘発性ゲノムプロファイルマーカー

Country Status (5)

Country Link
US (1) US20140235496A1 (https=)
EP (1) EP2764120B1 (https=)
JP (2) JP2014528247A (https=)
CA (1) CA2861668C (https=)
WO (1) WO2013052922A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502382A (ja) * 2015-12-30 2019-01-31 フジフィルム セルラー ダイナミクス，インコーポレイテッド 幹細胞由来ヒト肝細胞を使用した微小組織形成
JP2021523888A (ja) * 2018-04-30 2021-09-09 シーダーズ−サイナイ メディカル センター パーキンソン病におけるｐｋｃ経路

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935266C (en) * 2014-01-03 2022-02-01 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
CN105353135A (zh) * 2015-11-23 2016-02-24 中国人民解放军第三军医大学第一附属医院 阿尔茨海默病标志物的用途
US11415574B2 (en) 2017-03-31 2022-08-16 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
EP4262777A4 (en) * 2020-12-16 2025-01-01 Synaptogenix, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PKC ACTIVATORS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014588A1 (en) * 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
WO2011041761A1 (en) * 2009-10-02 2011-04-07 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of alzheimer's disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976816A (en) 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US6300085B1 (en) 1993-05-03 2001-10-09 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic method for Alzheimer's disease
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
EP1934618B1 (en) 2005-10-11 2009-05-13 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20080058396A1 (en) 2006-07-28 2008-03-06 Alkon Daniel L Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory
US20100040584A1 (en) * 2006-12-19 2010-02-18 Children's Medical Center Corporation Methods for promoting neovascularization
WO2010014585A1 (en) 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
KR101054725B1 (ko) * 2008-07-31 2011-08-05 재단법인서울대학교산학협력재단 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014588A1 (en) * 2008-07-28 2010-02-04 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
WO2011041761A1 (en) * 2009-10-02 2011-04-07 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of alzheimer's disease

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502382A (ja) * 2015-12-30 2019-01-31 フジフィルム セルラー ダイナミクス，インコーポレイテッド 幹細胞由来ヒト肝細胞を使用した微小組織形成
JP2021523888A (ja) * 2018-04-30 2021-09-09 シーダーズ−サイナイ メディカル センター パーキンソン病におけるｐｋｃ経路
US12564568B2 (en) 2018-04-30 2026-03-03 Cedars-Sinai Medical Center PKC pathway in Parkinson's Disease

Also Published As

Publication number Publication date
JP6636488B2 (ja) 2020-01-29
EP2764120A1 (en) 2014-08-13
EP2764120B1 (en) 2020-06-10
US20140235496A1 (en) 2014-08-21
CA2861668A1 (en) 2013-04-11
JP2018046826A (ja) 2018-03-29
CA2861668C (en) 2021-09-07
WO2013052922A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
JP6636488B2 (ja) 神経変性状態の刺激誘発性ゲノムプロファイルマーカー
Jiao et al. Identification of expanded repeats in NOTCH2NLC in neurodegenerative dementias
Vijayan et al. Peripheral biomarkers of stroke: focus on circulatory microRNAs
Yang et al. Increased interstitial white matter neuron density in the dorsolateral prefrontal cortex of people with schizophrenia
Pickett et al. The neuropathology of autism: a review
de Munain et al. Mutations in progranulin gene: clinical, pathological, and ribonucleic acid expression findings
Harris et al. Monocyte chemotactic protein-1 inhibits chondrogenesis of synovial mesenchymal progenitor cells: an in vitro study
Maekawa et al. Utility of scalp hair follicles as a novel source of biomarker genes for psychiatric illnesses
US8822166B2 (en) Stimulus-elicited genomic profile markers of alzheimer's disease
CA2877975C (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
JP5190654B2 (ja) 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
US20150166959A1 (en) Immortalized mesenchymal stromal cell from adipose tissue
JP2014521315A (ja) アルツハイマー病の診断
Cosma et al. Acute and chronic macrophage differentiation modulates TREM2 in a personalized Alzheimer’s patient-derived assay
US20120213769A1 (en) Methods of diagnosing amyotrophic lateral sclerosis (als)
Maurer-Morelli et al. A comparison between different reference genes for expression studies in human hippocampal tissue
Fan et al. Comparative transcriptome analysis reveals involvement of TLR-2 signaling in the pathogenesis of intracranial aneurysm
Terreni et al. Tumor necrosis factor α polymorphism C-850T is not associated with Alzheimer's disease and vascular dementia in an Italian population
US20090286238A1 (en) Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders
Ménesi et al. Gene and protein expression profiling of the fat-1 mouse brain
Xing et al. NEDD9 is genetically associated with Alzheimer's disease in a Han Chinese population
Yao et al. MRI features and significance of serum miRNAs and inflammatory cytokines in patients with temporal lobe epilepsy
Liang et al. Hedgehog signalling is downregulated in celiac disease
Szydlowska et al. miR-155-5p and miR-674-3p presence in peripheral blood and white blood cells as potential early biomarkers of temporal lobe epilepsy
van Wageningen et al. Distinct gene expression profiles in leukocortical demyelinated white and grey matter areas of Multiple Sclerosis patients

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20141212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171012

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20171208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190902